The Hippo signaling pathway is a developmental^ conserved pathway involved in organ size control, cellular proliferation and differentiation. Multiple lines of evidence suggest that deregulation of Hippo signaling plays a role in pancreatic cancer, include frequent overexpression of hYAP, the nuclear effector of mammalian Hippo signaling, in pancreatic cancer tissues and cell lines, and less commonly, somatic mutations of hF/4T7 and hFAT4, human orthologs of a Drosophila cadherin gene involved in Hippo repression and growth suppression. Ectopic hYAP expression in non-tumorigenic human pancreatic epithelial cells transforms these cells, while knockdown of endogenous hYAP by RNA interference in pancreatic cancer lines inhibits in vivo growth in athymic mice. The transcriptional targets of hYAP in human cells include genes associated with invasion, metastases, and tumor angiogenesis, as well as a limited cache of cancer-associated microRNAs (miRNAs). This proposal will provide functional annotation vis-a-vis the Hippo pathway in pancreatic cancer initiation and maintenance, using a variety of preclinical models. Specifically, in Aim 1,a role for Hippo pathway in pancreatic progenitor cell expansion will be studied using transgenic zebrafish with ectopic hYAP expression in the exocrine pancreas. The zebrafish studies will also elucidate whether common oncogenic and represser mutations found in human pancreatic cancer demonstrate genetic cooperation with hYAP in inducing pancreatic neoplasia.
In Aim 2, modulation of Hippo signaling will be studied in mammalian systems. Specifically, Yap will be conditionally ablated in a compound transgenic mouse model of pancreatic neoplasia and the effects on natural history of the disease and immunophenotype of resulting pancreatic lesions studied. Further, a panel of isogenic human pancreatic cancer lines will be generated by engineering missense mutations of hFAT1 and hFAT4 at their endogenous loci, in order to study the biochemical mechanisms associating the membrane bound FAT protocadherins to intracellular events in the Hippo pathway. Lastly, in Aim 3, hYAP-regulated miRNAs will be analyzed for their ability to recapitulate or rescue the phenotype of aberrant Hippo signaling in pancreatic cancer.
(Seeinstructions): Pancreatic cancer is a lethal disease and the understanding of altered signaling pathways will provide avenues for therapy and early diagnosis. We will study the role of Hippo signaling, which has been implicated throughout evolution in growth and size control, with regards to its role in pancreatic cancer.
|Hillion, Joelle; Roy, Sujayita; Heydarian, Mohammad et al. (2016) The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors. Gynecol Oncol 141:580-587|
|Choi, Eunyoung; Hendley, Audrey M; Bailey, Jennifer M et al. (2016) Expression of Activated Ras in Gastric Chief Cells of Mice Leads to the Full Spectrum of Metaplastic Lineage Transitions. Gastroenterology 150:918-30.e13|
|Hendley, Audrey M; Wang, Yue J; Polireddy, Kishore et al. (2016) p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. Cancer Res 76:3351-63|
|Roeser, J C; Leach, S D; McAllister, F (2015) Emerging strategies for cancer immunoprevention. Oncogene 34:6029-39|
|Chang, Tsung-Cheng; Pertea, Mihaela; Lee, Sungyul et al. (2015) Genome-wide annotation of microRNA primary transcript structures reveals novel regulatory mechanisms. Genome Res 25:1401-9|
|Knabel, Matthew K; Ramachandran, Kalyani; Karhadkar, Sunil et al. (2015) Systemic Delivery of scAAV8-Encoded MiR-29a Ameliorates Hepatic Fibrosis in Carbon Tetrachloride-Treated Mice. PLoS One 10:e0124411|
|Pertea, Mihaela; Pertea, Geo M; Antonescu, Corina M et al. (2015) StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol 33:290-5|
|Hendley, Audrey M; Provost, Elayne; Bailey, Jennifer M et al. (2015) p120 Catenin is required for normal tubulogenesis but not epithelial integrity in developing mouse pancreas. Dev Biol 399:41-53|
|Park, J T; Johnson, N; Liu, S et al. (2015) Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey. Oncogene 34:2801-6|
|Boj, Sylvia F; Hwang, Chang-Il; Baker, Lindsey A et al. (2015) Organoid models of human and mouse ductal pancreatic cancer. Cell 160:324-38|
Showing the most recent 10 out of 65 publications